Generation Bio Co. financial data

Symbol
GBIO on Nasdaq
Industry
Pharmaceutical Preparations
Location
301 Binney Street, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 877 % -47.7%
Debt-to-equity 76.2 % +110%
Return On Equity -82.3 % -84%
Return On Assets -46.7 % -42.3%
Operating Margin -1.82 K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66.5 M shares +1.22%
Common Stock, Shares, Outstanding 66.5 M shares +1.44%
Entity Public Float 299 M USD -2.16%
Common Stock, Value, Issued 7 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 66.4 M shares +10.3%
Weighted Average Number of Shares Outstanding, Diluted 66.4 M shares +10.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.96 M USD
Research and Development Expense 86 M USD -7.74%
General and Administrative Expense 48.4 M USD +1.83%
Operating Income (Loss) -181 M USD -28.9%
Nonoperating Income (Expense) 12.3 M USD +76.1%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -169 M USD -26.4%
Earnings Per Share, Basic -2.55 USD/shares -12.3%
Earnings Per Share, Diluted -2.55 USD/shares -12.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.5 M USD -62.9%
Marketable Securities, Current 184 M USD -4.78%
Other Assets, Current 290 K USD +12%
Assets, Current 227 M USD -34.2%
Property, Plant and Equipment, Net 18.6 M USD -15.6%
Operating Lease, Right-of-Use Asset 23 M USD -60.4%
Other Assets, Noncurrent 253 K USD -56.6%
Assets 286 M USD -33.7%
Accounts Payable, Current 1.48 M USD -1.46%
Employee-related Liabilities, Current 4.04 M USD +34.1%
Contract with Customer, Liability, Current 5.68 M USD
Liabilities, Current 28.3 M USD +24.5%
Contract with Customer, Liability, Noncurrent 55.1 M USD
Operating Lease, Liability, Noncurrent 87.6 M USD +17.6%
Liabilities 154 M USD +1.06%
Accumulated Other Comprehensive Income (Loss), Net of Tax -197 K USD -679%
Retained Earnings (Accumulated Deficit) -646 M USD -35.5%
Stockholders' Equity Attributable to Parent 132 M USD -52.7%
Liabilities and Equity 286 M USD -33.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.7 M USD -14.5%
Net Cash Provided by (Used in) Financing Activities -125 K USD -100%
Net Cash Provided by (Used in) Investing Activities -553 K USD +90.2%
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 66.5 M shares +1.44%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 39.9 M USD -60.7%
Deferred Tax Assets, Valuation Allowance 176 M USD +27.3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 61.5 M USD
Payments to Acquire Property, Plant, and Equipment 1.92 M USD +154%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -169 M USD -26.6%
Lessee, Operating Lease, Liability, to be Paid 137 M USD +31.1%
Property, Plant and Equipment, Gross 38.9 M USD +2.71%
Operating Lease, Liability, Current 8.37 M USD +5.86%
Lessee, Operating Lease, Liability, to be Paid, Year Two 15.6 M USD +2.83%
Lessee, Operating Lease, Liability, to be Paid, Year One 15.2 M USD +13.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 38.9 M USD -13.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 16.1 M USD +2.92%
Deferred Tax Assets, Operating Loss Carryforwards 96.9 M USD +8.26%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 16.6 M USD +2.83%
Operating Lease, Payments 1.9 M USD -38.7%
Additional Paid in Capital 778 M USD +2.93%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 5.25 M USD -0.34%
Deferred Tax Assets, Net of Valuation Allowance 198 M USD +25.3%
Share-based Payment Arrangement, Expense 22.1 M USD -10.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%